Core Insights - Kuros Biosciences has successfully completed the first U.S. cases using the new MagnetOs MIS Delivery System, marking a significant milestone in enhancing surgeon access to a streamlined graft delivery approach [1][2] - The company is expanding its global presence with the recent approval of MagnetOs Putty in Brazil, reflecting increasing demand for its products in the South American market [5][6] Product Launch and Features - The MagnetOs MIS Delivery System is a sterile, prefilled, single-use system designed for Minimally Invasive Surgery (MIS) in spine procedures, which received FDA 510(k) clearance in May [1][2] - The system allows for faster graft placement, achieving it three times faster than traditional methods, thus optimizing operating room time [3] Clinical Evidence and Performance - MagnetOs has demonstrated a 94.4% fusion rate in a retrospective study involving patients undergoing MIS and open transforaminal lumbar interbody fusions (TLIF), with many patients having comorbidities [4] - In a Level I clinical study, MagnetOs achieved nearly double the fusion rate of autograft in posterolateral fusions (79% vs. 47%) [8] Market Expansion - The approval of MagnetOs Putty in Brazil signifies the company's entry into the South American spine and orthopedic market, indicating strong projected market growth [5][6] - Kuros aims to accelerate access to its technology in key international markets, capitalizing on the rising demand for minimally invasive surgical techniques [6]